NASDAQ:TCDA

Tricida Competitors

$5.09
+0.14 (+2.83 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.83
Now: $5.09
$5.17
50-Day Range
$4.52
MA: $5.36
$7.66
52-Week Range
$3.74
Now: $5.09
$32.99
Volume276,223 shs
Average Volume728,426 shs
Market Capitalization$255.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4

Competitors

Tricida (NASDAQ:TCDA) Vs. PAHC, ENTA, ARCT, AKRO, EPIX, and ANNX

Should you be buying TCDA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Tricida, including Phibro Animal Health (PAHC), Enanta Pharmaceuticals (ENTA), Arcturus Therapeutics (ARCT), Akero Therapeutics (AKRO), ESSA Pharma (EPIX), and Annexon (ANNX).

Phibro Animal Health (NASDAQ:PAHC) and Tricida (NASDAQ:TCDA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Profitability

This table compares Phibro Animal Health and Tricida's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Phibro Animal Health5.37%23.70%5.99%
TricidaN/A-125.57%-69.25%

Analyst Recommendations

This is a summary of current recommendations for Phibro Animal Health and Tricida, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Phibro Animal Health11001.50
Tricida11202.25

Phibro Animal Health presently has a consensus price target of $21.50, indicating a potential downside of 12.39%. Tricida has a consensus price target of $19.50, indicating a potential upside of 283.10%. Given Tricida's stronger consensus rating and higher probable upside, analysts clearly believe Tricida is more favorable than Phibro Animal Health.

Risk and Volatility

Phibro Animal Health has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Tricida has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500.

Institutional and Insider Ownership

50.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 70.5% of Tricida shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 70.4% of Tricida shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Phibro Animal Health and Tricida's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phibro Animal Health$800.40 million1.24$33.55 million$1.0822.72
TricidaN/AN/A$-176,810,000.00($3.72)-1.37

Phibro Animal Health has higher revenue and earnings than Tricida. Tricida is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Summary

Phibro Animal Health beats Tricida on 7 of the 13 factors compared between the two stocks.

Enanta Pharmaceuticals (NASDAQ:ENTA) and Tricida (NASDAQ:TCDA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Profitability

This table compares Enanta Pharmaceuticals and Tricida's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enanta Pharmaceuticals-29.53%-3.75%-3.53%
TricidaN/A-125.57%-69.25%

Analyst Recommendations

This is a summary of current recommendations for Enanta Pharmaceuticals and Tricida, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enanta Pharmaceuticals13302.29
Tricida11202.25

Enanta Pharmaceuticals presently has a consensus price target of $65.2857, indicating a potential upside of 33.92%. Tricida has a consensus price target of $19.50, indicating a potential upside of 283.10%. Given Tricida's higher probable upside, analysts clearly believe Tricida is more favorable than Enanta Pharmaceuticals.

Risk and Volatility

Enanta Pharmaceuticals has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Tricida has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500.

Institutional and Insider Ownership

90.8% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.5% of Tricida shares are owned by institutional investors. 10.9% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 70.4% of Tricida shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Enanta Pharmaceuticals and Tricida's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enanta Pharmaceuticals$122.47 million8.03$-36,170,000.00($0.89)-54.78
TricidaN/AN/A$-176,810,000.00($3.72)-1.37

Enanta Pharmaceuticals has higher revenue and earnings than Tricida. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Tricida, indicating that it is currently the more affordable of the two stocks.

Summary

Enanta Pharmaceuticals beats Tricida on 8 of the 13 factors compared between the two stocks.

Arcturus Therapeutics (NASDAQ:ARCT) and Tricida (NASDAQ:TCDA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for Arcturus Therapeutics and Tricida, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcturus Therapeutics25402.18
Tricida11202.25

Arcturus Therapeutics presently has a consensus price target of $70.6667, indicating a potential upside of 90.99%. Tricida has a consensus price target of $19.50, indicating a potential upside of 283.10%. Given Tricida's stronger consensus rating and higher probable upside, analysts clearly believe Tricida is more favorable than Arcturus Therapeutics.

Earnings & Valuation

This table compares Arcturus Therapeutics and Tricida's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcturus Therapeutics$20.79 million46.77$-25,990,000.00($2.15)-17.21
TricidaN/AN/A$-176,810,000.00($3.72)-1.37

Arcturus Therapeutics has higher revenue and earnings than Tricida. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Tricida, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

74.3% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 70.5% of Tricida shares are owned by institutional investors. 12.6% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 70.4% of Tricida shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Arcturus Therapeutics and Tricida's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcturus Therapeutics-506.70%-52.32%-33.21%
TricidaN/A-125.57%-69.25%

Risk and Volatility

Arcturus Therapeutics has a beta of 3.01, meaning that its stock price is 201% more volatile than the S&P 500. Comparatively, Tricida has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500.

Summary

Arcturus Therapeutics beats Tricida on 8 of the 13 factors compared between the two stocks.

Tricida (NASDAQ:TCDA) and Akero Therapeutics (NASDAQ:AKRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.

Profitability

This table compares Tricida and Akero Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TricidaN/A-125.57%-69.25%
Akero TherapeuticsN/A-40.84%-38.33%

Institutional & Insider Ownership

70.5% of Tricida shares are held by institutional investors. Comparatively, 83.5% of Akero Therapeutics shares are held by institutional investors. 70.4% of Tricida shares are held by company insiders. Comparatively, 7.1% of Akero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Tricida and Akero Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TricidaN/AN/A$-176,810,000.00($3.72)-1.37
Akero TherapeuticsN/AN/A$-43,760,000.00($2.90)-9.57

Akero Therapeutics is trading at a lower price-to-earnings ratio than Tricida, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Tricida and Akero Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tricida11202.25
Akero Therapeutics00703.00

Tricida currently has a consensus price target of $19.50, indicating a potential upside of 283.10%. Akero Therapeutics has a consensus price target of $57.2857, indicating a potential upside of 106.36%. Given Tricida's higher probable upside, research analysts plainly believe Tricida is more favorable than Akero Therapeutics.

Volatility and Risk

Tricida has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Summary

Akero Therapeutics beats Tricida on 7 of the 11 factors compared between the two stocks.

Tricida (NASDAQ:TCDA) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.

Profitability

This table compares Tricida and ESSA Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TricidaN/A-125.57%-69.25%
ESSA PharmaN/A-46.31%-45.08%

Institutional & Insider Ownership

70.5% of Tricida shares are held by institutional investors. Comparatively, 63.4% of ESSA Pharma shares are held by institutional investors. 70.4% of Tricida shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Tricida and ESSA Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TricidaN/AN/A$-176,810,000.00($3.72)-1.37
ESSA PharmaN/AN/A$-23,440,000.00($1.04)-27.28

ESSA Pharma is trading at a lower price-to-earnings ratio than Tricida, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Tricida and ESSA Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tricida11202.25
ESSA Pharma00503.00

Tricida currently has a consensus target price of $19.50, indicating a potential upside of 283.10%. ESSA Pharma has a consensus target price of $28.80, indicating a potential upside of 1.52%. Given Tricida's higher probable upside, equities analysts plainly believe Tricida is more favorable than ESSA Pharma.

Volatility & Risk

Tricida has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500.

Summary

ESSA Pharma beats Tricida on 7 of the 11 factors compared between the two stocks.

Tricida (NASDAQ:TCDA) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Tricida and Annexon, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tricida11202.25
Annexon00503.00

Tricida currently has a consensus target price of $19.50, indicating a potential upside of 283.10%. Annexon has a consensus target price of $34.3333, indicating a potential upside of 37.72%. Given Tricida's higher probable upside, equities analysts plainly believe Tricida is more favorable than Annexon.

Profitability

This table compares Tricida and Annexon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TricidaN/A-125.57%-69.25%
AnnexonN/A-566.22%-32.99%

Earnings & Valuation

This table compares Tricida and Annexon's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TricidaN/AN/A$-176,810,000.00($3.72)-1.37
AnnexonN/AN/A$-37,180,000.00N/AN/A

Institutional & Insider Ownership

70.5% of Tricida shares are held by institutional investors. Comparatively, 91.2% of Annexon shares are held by institutional investors. 70.4% of Tricida shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Annexon beats Tricida on 5 of the 8 factors compared between the two stocks.


Tricida Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.54+0.1%$992.72 million$800.40 million23.15News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$48.75+1.1%$983.39 million$122.47 million-26.79News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$37.00+1.8%$972.36 million$20.79 million-12.76
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.76+1.9%$965.22 millionN/A-12.79
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$28.37+0.2%$958.34 millionN/A-26.27
Annexon logo
ANNX
Annexon
1.9$24.93+0.9%$951.28 millionN/A0.00
Humanigen logo
HGEN
Humanigen
1.6$17.25+1.9%$922.56 millionN/A0.00
Radius Health logo
RDUS
Radius Health
1.3$19.49+2.0%$913.96 million$173.32 million-7.99News Coverage
Prothena logo
PRTA
Prothena
2.3$22.78+3.1%$911.34 million$810,000.00-8.90Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.25+2.2%$891.85 million$227.19 million45.14Analyst Upgrade
Gap Down
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$35.87+0.4%$881.43 millionN/A-10.64Analyst Report
Gap Down
Merus logo
MRUS
Merus
1.6$23.06+1.0%$879.21 million$31.13 million-7.51Analyst Report
Analyst Revision
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$16.75+0.0%$861.92 millionN/A0.00
Affimed logo
AFMD
Affimed
1.6$9.74+19.0%$860.30 million$23.96 million-16.51Unusual Options Activity
Analyst Revision
News Coverage
Gap Down
Epizyme logo
EPZM
Epizyme
1.8$8.37+0.6%$851.94 million$23.80 million-3.75
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.89+0.6%$848.58 million$322.36 million127.79
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.33+1.3%$810.86 million$296.70 million47.61
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.57+7.5%$791.51 millionN/A0.00Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37+1.1%$775.18 million$322.07 million-5.11
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$26.95+4.7%$753.06 million$148.36 million-7.00Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.02+1.2%$747.83 million$40.89 million-3.46
Veru logo
VERU
Veru
1.4$10.35+0.3%$744.29 million$42.59 million-36.96
Ardelyx logo
ARDX
Ardelyx
1.6$7.44+5.6%$734.18 million$5.28 million-7.37Gap Down
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17+5.3%$731.97 million$252 million-2.27Gap Down
Chimerix logo
CMRX
Chimerix
1.3$8.45+2.1%$723.99 million$12.52 million-14.82News Coverage
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.82+1.8%$716.29 million$2.22 million-16.59
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32+2.1%$714.48 million$150,000.00-4.74Gap Down
OrganiGram logo
OGI
OrganiGram
1.6$3.05+3.3%$708.43 million$64.61 million-4.49Upcoming Earnings
Analyst Upgrade
Gap Down
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.50+0.0%$686.58 million$19.56 million-19.78High Trading Volume
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.74+3.3%$660.12 millionN/A-2.46Gap Down
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$28.38+13.7%$655.29 million$13.80 million-13.71Insider Selling
High Trading Volume
Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.23+5.6%$651.22 million$143.01 million-1.19Gap Down
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$19.86+9.5%$640.68 millionN/A-10.56Gap Down
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$26.15+0.1%$635.65 million$12.69 million-12.57
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$17.62+1.3%$630.96 million$6.83 million-18.16News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.66+5.2%$628.85 million$5.09 million-6.10Analyst Upgrade
Gap Down
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.88+2.4%$628.47 million$9.64 million-5.36
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.82+3.0%$624.78 million$17.26 million-4.12Earnings Announcement
Analyst Revision
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$12.32+9.9%$598.21 millionN/A-6.32Analyst Upgrade
News Coverage
Gap Down
Evolus logo
EOLS
Evolus
1.1$13.58+2.4%$593.89 million$34.92 million-6.69Analyst Report
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$35.23+2.0%$590.00 millionN/A-16.31
AnaptysBio logo
ANAB
AnaptysBio
1.5$20.87+6.3%$571.13 million$8 million-7.70Gap Down
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.04+4.1%$568.85 millionN/A-9.33Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.52+3.3%$567.69 millionN/A-4.47News Coverage
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$17.07+4.9%$563.81 million$1.19 million-7.11Insider Buying
News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
0.0$14.44+2.2%$557.76 millionN/A0.00
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26+1.8%$554.59 million$59.29 million-21.73
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.20+5.2%$553.64 millionN/A-5.29Analyst Upgrade
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.4$41.56+0.9%$549.30 million$195.89 million118.75News Coverage
SIGA
SIGA Technologies
0.3$7.10+0.6%$544.91 million$26.74 million17.75
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.